Faculty of Medicine Ramathibodi Hospital
Department of Clinical Epidemiology and Biostatistics

# Data management $\&$ <br> <br> Statistical analysis 

 <br> <br> Statistical analysis}

Sasivimol Rattanasiri, Ph.D<br>Department of Clinical Epidemiology and Biostatistics<br>Ramathibodi Hospital, Mahidol University<br>E-mail: sasivimol.rat@mahidol.edu<br>www.ceb-rama.org

## Research question

## Data management

## Statistical analysis

Faculty of Medicine Ramathibodi Hospital
Department of Clinical Epidemiology and Biostatistics

## Scope



## Understand basic questions...



> What are objectives of research?

What is type of study design?

What variables will be involved?

How variables will be measured?

How often variables will be collected?

## Understand basic questions...




## Research question

A retrospective cohort study of kidney transplantation
(KT) patients was conducted to assess the association
between types of donors and risk of graft failure


## Understand basic questions...





## Understand basic questions...



Factors associated with graft failure


## Understand basic questions...



Factors associated with graft failure

|  |  |  |
| :--- | :--- | :--- |
| 1. Date of birth | $\square \square / \square \square / \square \square \square \square$ (DD/MM/MYY) |  |
| 2. Gender | $\square$ 1. Male | $\square$ 2. Female |
| 3. Types of donor | $\square 1$. CDKT | $\square$ 2. LRKT |
| 4. Weight | $\square \square \square \mathrm{kg}$. |  |
| 5. Height | $\square \square \mathrm{cm}$. |  |

Factors associated with graft failure

|  |  |  |
| :--- | :--- | :--- |
| 1. Date of visit | $\square \square / \square \square / \square \square \square \square$ (DD/MM/MYY) |  |
| 2. Graft status | $\square$ 1. failure $\quad \square$ 2. function |  |
| 3. Date of failure | $\square \square / \square \square / \square \square \square \square$ (DD/MM/MMY) |  |
| 4. Serum creatinine | $\square \square \mathrm{mg} / \mathrm{dL}$ |  |
| 5. Serum albumin | $\square \square \mathrm{g} / \mathrm{dL}$ |  |

## Understand basic questions...



How often variable will be collected...


Types of donor
.......... $\rightarrow$ collected every 6 months after KT
collected at the enrollment period


Faculty of Medicine Ramathibodi Hospital
Department of Clinical Epidemiology and Biostatistics

## Scope

## Data management

## Data management



## Case Record Form (CRF)

## " a paper or electronic form designed to collect all of data , which specifies by study protocol



## Poorly designed CRF

## Well designed CRF

| Poorly designed | Well designed |
| :---: | :---: |
| Date of visit: | Date of visit: (DD/MM/YYYY) |
| Blood pressure: ___ | Blood pressure: $\square$ $\square /$ $\square$ $\square \square$ ( mmHg ) |
| Pulse: | Pulse: $\square \square \square$ (beats/min) |
| Temperature: | Temperature: $\square \square . \square$ ( ${ }^{\circ} \mathrm{C}$ ) |
| Respiration: ___ | Respiration: $\square \square$ (/min) |

Provide boxes to hold answers

Unit of measurement did not display on CRF

Units and decimal points should be displayed

## Objective of CRF design...

| Preserve and <br> maintain | Quality and integrity of data |
| :---: | :--- |
| Gather | Complete and accurate data |
| Avoid | Duplication of data |
| Facilitate | Transcription of data from sources documents onto CRF |

Mahidol University

Faculty of Medicine Ramathibodi Hospital

## How to prepare data in Excel...



## Cross-sectional data

Follow-up data

## Cross-sectional data

| Subject | Age | Sex | Group | Response |
| :---: | :---: | :---: | :---: | :---: |
| 1 | 32 | Female | Treatment | No |
| 2 | 45 | Female | Control | No |
| 3 | 23 | Male | Control | Yes |
| 4 | 38 | Female | Treatment | No |
| 5 | 36 | Male | Control | Yes |
| 6 | 29 | Male | Control | Yes |
| 7 | 43 | Male | Treatment | Yes |
| 8 | 39 | Female | Control | No |
| 9 | 51 | Male | Treatment | Yes |
| 10 | 42 | Female | Treatment | No |

Variable name

- Not exceed than 10 characters
- Not contain space
- Not begin with number


## Cross-sectional data

| Subject | Age | Sex | Group | Response |
| :---: | :---: | :---: | :---: | :---: |
| 1 | 32 | Female | Treatment | No |
| 2 | 45 | Female | Control | No |
| 3 | 23 | Male | Control | Yes |
| 4 | 38 | Female | Treatment | No |
| 5 | 36 | Male | Control | Yes |
| 6 | 29 | Male | Control | Yes |
| 7 | 43 | Male | Treatment | Yes |
| 8 | 39 | Female | Control | No |
| 9 | 51 | Male | Treatment | Yes |
| 10 | 42 | Female | Treatment | No |

## Types of Data

- Only numerical data
- Set special for missing data


## Cross-sectional data

| Subject | Sex | Group | Response |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Female | Treatment | No |  |  |  |  |
| 2 | Female | Control | No |  |  |  |  |
| 3 | Male | Control | Yes |  |  |  |  |
| 4 | Female | Treatment | No |  |  |  |  |
| 5 | Male | Control | Yes | Subject | Sex | Group | Response |
| 1. Male <br> 1. Treatment <br> 2. Female <br> 2. Control |  |  | $\begin{aligned} & \text { 1. Yes } \\ & \text { 2. No } \end{aligned}$ | 1 | 2 | 1 | 2 |
|  |  |  | 2 | 2 | 2 | 2 |
|  |  |  | 3 | 1 | 2 | 1 |
|  |  |  | 4 | 2 | 1 | 2 |
|  |  |  | 5 | 1 | 2 | 1 |

## Cross-sectional data

| Subject | DM | HT | CVD | Malignant |
| :---: | :---: | :---: | :---: | :---: |
| 1 | 1 | 2 | 1 | 2 |
| 2 | 1 | 2 | 2 | 2 |
| 3 | 2 | 1 | 2 | 1 |
| 4 | 1 | 2 | 1 | 2 |
| 5 | 2 | 1 | 2 | 1 |
| 6 | 2 | 1 | 2 | 1 |
| 7 | 1 | 1 | 1 | 1 |
| 8 | 1 | 2 | 2 | 2 |
| 9 | 2 | 1 | 1 | 1 |
| 10 | 1 | 2 | 1 | 2 |

Use consistency code

1. Yes
2. No

## Cross-sectional data

| Subject | TAC | Dose_TAC | MMF | Dose_MMF |
| :---: | :---: | :---: | :---: | :---: |
| 1 | 1 | 0.5 | 1 | 180 |
| 2 | 1 | 1.5 | 2 | 0 |
| 3 | 2 | 0 | 2 | 0 |
| 4 | 1 | 3.5 | 1 | 360 |
| 5 | 2 | 0 | 2 | 0 |
| 6 | 2 | 0 | 2 | 0 |
| 7 | 1 | 2.5 | 1 | 180 |
| 8 | 1 | 3 | 2 | 0 |
| 9 | 2 | 0 | 1 | 540 |
| 10 | 1 | 2.5 | 1 | 360 |

Dose format

- Specify unit for data entry (mg/day)
- Enter "0" for not receive treatment


## Follow-up data: Long format

| Subject | Visit | Date visit | SBP | DBP | Response |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 1 | $12 / 08 / 2000$ | 90 | 65 | 2 |
| 1 | 2 | $05 / 09 / 2000$ | 95 | 60 | 2 |
| 1 | 3 | $11 / 12 / 2000$ | 90 | 65 | 1 |
| 2 | 1 | $16 / 03 / 2011$ | 120 | 80 | 2 |
| 2 | 2 | $09 / 07 / 2011$ | 125 | 85 | 1 |
| 3 | 1 | $06 / 12 / 2012$ | 100 | 85 | 2 |
| 3 | 2 | $08 / 06 / 2013$ | 105 | 90 | 2 |
| 3 | 3 | $10 / 09 / 2013$ | 110 | 90 | 2 |
| 4 | 1 | $23 / 04 / 2008$ | 150 | 95 | 2 |
| 4 | 2 | $19 / 11 / 2008$ | 155 | 98 | 1 |

Mahidol University

Faculty of Medicine Ramathibodi Hospital
Department of Clinical Epidemiology and Biostatistics

## Follow-up data: Wide format

| Subject | date1 | SBP1 | DBP1 | resp1 | date2 | SBP2 | DBP2 | resp2 | date... | SBP... |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 |  |  |  |  |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |  |  |  |  |
| 5 |  |  |  |  |  |  |  |  |  |  |

## Inappropriate data format

| L15 | $\checkmark$ - | $\times \vee f_{x}$ | 0.2 |  |  |  |  | Not appropriate format for statistical analysis |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 4 | Q | R | S | T | U | V | W |  |
|  | SARS Cov 2 IgG Spike Protein (AU/ml) | SARS Cov 2 IgG Spike Protein (BAU/ml) | \% IH Euroimmune | \%inhibition (sVNT-delta) | IGRA T Cell |  |  |  |
| 4 |  |  |  |  | วันที่เจาะเลือด | Interpretation | Value ( $\mathrm{mlV} / \mathrm{ml}$ ) |  |
| 5 | 2.6 | 0.37 |  |  |  |  |  | Incorrect variable name |
| 6 | 0.1 | 0.01 | -3.56 | -13.10 |  |  |  |  |
| 7 | 0.2 | 0.03 |  |  | 9/22/2564 | Negative | 30.3 |  |
| 8 | 2.6 | 0.37 |  |  |  |  |  |  |
| 9 | 56.4 | 8.01 | -17.03 |  |  |  |  |  |
| 10 | 15.8 | 2.24 |  |  | 26/9/2564 | Negative | -1.2 |  |

## Wisdam of the Land

Faculty of Medicine Ramathibodi Hospital
Department of Clinical Epidemiology and Biostatistics

## Inappropriate data format

| IGRA T Cell |  |  | CODE | วันที่เจาะเลือด | ระยะเวลาเจาะ เลือดหลังฉีด วัคซีนเข็ม 2 | SARS Cov 2 IgG Spike Protein ( $\mathrm{AU} / \mathrm{ml}$ ) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| วันที่เจาะเลือด | Interpretation | Value (mIU/ml) |  |  |  |  |
|  |  |  | H3 | 10/2/2564 | 22 | 4.6 |
|  |  |  | H4 | 8/13/2564 | 14 | 5.0 |
| 9/22/2564 | Negative | 30.3 | H6 | 10/6/2564 | 14 | 3.5 |
|  |  |  | H8 | 10/1/2564 | 16 | 4.8 |
|  |  |  | H10 | 10/1/2564 | 23 | 1096.8 |
| 26/9/2564 | Negative | -1.2 | H11 | 10/16/2564 | 13 | 36.6 |
|  |  |  | H13 | 10/5/2564 | 36 | 4.2 |

## Incorrect variable name

## Wiadom of the Land

## Inappropriate data format

Not appropriate format for underlying disease

| underlying |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |
|  | HTN | CAD | DM | hepatitis | Cancer | SLE |
| HT | 1 | 0 | 0 | 0 | 0 | 0 |
| DM, HT , CAD | 1 | 1 | 1 | 0 | 0 | 0 |
| DM,HT | 1 | 0 | 1 | 0 | 0 | 0 |
| HT | 1 | 0 | 0 | 0 | 0 | 0 |
| HT | 1 | 0 | 0 | 0 | 0 | 0 |
| HT | 1 | 0 | 0 | 0 | 0 | 0 |
| DM, HT , CAD | 1 | 1 | 1 | $0$ | 0 | 0 |

## Inappropriate data format

|  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |



## Wiadom of the Land

## Appropriate long format for follow-up data

| Subject | vaccine | neoral | prograf | cellcept | myfortic | pred |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 1 | 0 | 5 | 1000 | 0 | 5 |
| 1 | 2 | 0 | 4 | 1500 | 180 | 5 |
| 2 | 1 | 0 | 1.5 | 1000 | 360 | 5 |
| 2 | 2 | 100 | 1 | 0 | 720 | 5 |
| 3 | 1 | 0 | 0 | 1250 | 0 | 5 |
| 3 | 2 | 150 | 4 | 0 | 180 | 5 |
| 4 | 1 | 0 | 2 | 1000 | 0 | 5 |
| 4 | 2 | 0 | 0 | 1500 | 720 | 5 |
| 5 | 1 | 100 | 3.5 | 0 | 360 | 5 |
| 5 | 2 | 150 | 0 | 0 | 180 | 5 |

Appropriate wide format for follow-up data

| Subject | neoral1 | prograf1 | cellcept1 | myfortic1 | neoral2 | prograf2 | cellcept2 | myfortic2 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 0 | 5 | 1000 | 0 | 100 | 5 | 1000 | 0 |
| 2 | 0 | 4 | 1500 | 180 | 150 | 4 | 1500 | 180 |
| 3 | 0 | 1.5 | 1000 | 360 | 0 | 1.5 | 1000 | 360 |
| 4 | 100 | 1 | 0 | 720 | 0 | 1 | 0 | 720 |
| 5 | 0 | 0 | 1250 | 0 | 100 | 0 | 1250 | 0 |
| 6 | 150 | 4 | 0 | 180 | 0 | 4 | 0 | 180 |
| 7 | 0 | 2 | 1000 | 0 | 150 | 2 | 1000 | 0 |
| 8 | 0 | 0 | 1500 | 720 | 100 | 0 | 1500 | 720 |
| 9 | 100 | 3.5 | 0 | 360 | 0 | 3.5 | 0 | 360 |
| 10 | 150 | 0 | 0 | 180 | 150 | 0 | 0 | 180 |






## Types of data

## Categorical data

- Nominal data
- Ordinal data


## Numerical data

- Discrete data
- Continuous data


## Categorical data

Nominal data

Sex: male/female ->dichotomous data
Blood group: $A / B / A B / O$
Degree of injury: mild/moderate/severe
Stage of cancer: I/II/III/IV

## Numerical data

| Discrete data | Length of hospital stay |
| :---: | :--- |
|  | Number of heart beats per minute |
| Continuous data | Cholesterol level (mg/dL) |
|  | Fasting blood sugar (mg/dL) |

## Types of statistics




## Summarizing: Categorical data

| Sex | Frequency | Percentage |
| :--- | :---: | :---: |
| Male | 56 | 80 |
| Female | 14 | 20 |
| Total | 70 | 100 |


|  | I | 120 | 15 |
| :---: | :---: | :---: | :---: |
| Ordinal data | II | 320 | 40 |
|  | III | 160 | 20 |
|  | IV | 200 | 25 |
|  | Total | 800 | 100 |

## Summarizing: Numerical data



## Summarizing: Numerical data

|  | Mean | SD |
| :--- | :---: | :---: |
| Age (year) | 49.6 | 14.3 |
| Weight (cm) | 95.6 | 21.7 |
| Height (cm) | 161.5 | 9.2 |

## Normal distribution

|  | Mean | SD |
| :--- | :---: | :---: |
| CD4 count | 62.4 | 74.4 |
| CAscore | 177.7 | 352.9 |
|  | Median | Range |
| CD4 count | 30.5 | 1,358 |
| CA score | 51.0 | 1,4879 |

Mahidol University
Faculty of Medicine Ramathibodi Hospital
Department of Clinical Epidemiology and Biostatistics

## Summarizing data



## Dummy table for descriptive data

## Characteristics

## Gender; n (\%)

Male
Female
Age; years; mean (sd)
Age; n (\%)
<30 years
$\geq 30$ years
Body weight; kg; mean (sd)
Diabetes; n (\%)
Yes
No



## Inferential statistics

## Parameter estimation

- Point estimate
- Range estimate

Hypothesis testing

- Single population
- Two population
- More than two pop.


## Inferential statistics

## Parameter estimation

- Point estimate
- Range estimate

Hypothesis testing

Single population
Two population
More than two nor.

## Parameter estimation

> Estimation of mean age of patients who had breast cancer in Thailand
> Estimation prevalence of chronic kidney disease in Thai population


## Continuous data

| Point estimate | The mean age of 750 patients with DM <br> was 54.42 years |
| :--- | :--- |
| Range estimate | 95\% CI of mean age range from 43.65 <br> years to 62.34 years |

## Categorical data

| Point estimate | 42 in 350 subjects had hypertension, <br> prevalence of hypertension was 0.12 |
| :--- | :--- |
| Range estimate | $95 \%$ CI of the prevalence of hypertension <br> was from 0.09 to 0.15 |

## Recommendation

- Point estimate should be reported with their confidence intervals to indicate their precision
© Prevalence of HT was $12 \%$ with $95 \%$ CI: 9-15\%



## Inferential statistics



## Hypothesis testing

- Single population
- Two population
- More than two pop.


## Hypothesis testing

## Continuous outcome

Test if the means of BMD
between postmenopausal women who received and did not receive calcium supplements differ.

## Dichotomous outcome

Assess the association
between traditional medicine used and osteoporotic hip fracture.

## Types of errors




## Hypothesis testing

## Null hypothesis



II. Hypothesis testing

- Categorical outcome
- Continuous outcome


## Hypothesis testing for categorical data

| Tests of association |
| :---: |
| Independent sample |
| Paired-sample |

## Hypothesis testing for categorical data

## Tests of association

Independent sample


## Independent sample

- A case-control study was conducted to look at effect of traditional medicine and osteoporotic hip fracture.

2 The outcome of interest was osteoporotic hip fracture.
ə The exposure of interest was traditional medicine.

## $2 \times 2$ contingency table for independent sample

| Hip fracture | Traditional medicine used |  |  |
| :--- | :---: | :---: | :---: |
|  | Yes | No | n |
| Yes | 20 | 208 | 228 |
| No | 8 | 216 | 224 |

## Statistical analysis

© The Chi-square test is used to examine association between two categorical variables
ə $\mathrm{H}_{0}$ : The proportions of the interested event between two independent groups are not different
○ $\mathrm{H}_{0}$ : Two categorical variables are independent
$\mathrm{H}_{0}$ : No association between traditional medicine and hip fracture

## Conclusion

- Reject null hypothesis
© There was association between traditional medicine and hip fracture
tab tredmed hip,col exp chi2


> Wiadam of the Land

## Statistical analysis

( The Chi-square test is not appropriate if small sample.
© Expected frequency is less than 5 for more than $20 \%$ of the total cells
© The Fisher's exact test is an alternative method

## Independent with small sample

- A case-control study was conducted to look at effect of receiving HRT on risk of hip fracture.
- The outcome of interest was hip fracture.
© The exposure of interest was HRT.


## $2 \times 2$ contingency table for independent sample

| Hip fracture |  | HRT |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Yes | No | n |  |
| Yes | 1 | 213 | 214 |  |
| No | $(1.5)$ | $(212.5)$ |  |  |
|  | 2 | 214 | 216 |  |

$\mathrm{H}_{0}$ : No association between HRT and hip fracture

## Conclusion

- Fail to reject null hypothesis
© There was no association between HRT and hip fracture
tab hrt hip,col exp exact




## Fisher's exact =

1.000

1-sided Fisher's exact $=$
0.503
Wiadom of the Land

| Characteristics | Hip fracture | Non-hip fracture | P value |
| :--- | :---: | :---: | :---: |
|  | $\mathrm{n}(\%)$ | $\mathrm{n}(\%)$ |  |
| Age, year |  |  |  |
| $<60$ |  |  |  |
| $\geq 60$ |  |  |  |
| Gender |  |  |  |
| Male |  |  |  |
| Femal |  |  |  |
| Hypertension |  |  |  |
| Yes |  |  |  |
| No |  |  |  |

## Hypothesis testing for categorical data

## Tests of association

## Independent sample

Paired-sample

## Paired sample

- Comparison of pain relief (yes/no) by two different analgesics in the same subjects.

2 In a matched case-control study, matched case to control patients with BMI , aim to assess the association between HRT and the hip fracture.

## $2 \times 2$ contingency table for paired sample

| Case |  |  |  |
| :--- | :---: | :---: | :---: |
|  | Control |  |  |
|  | HRT+ | HRT- | n |
| HRT+ | 102 | 50 | 152 |
| HRT- | 100 | 120 | 220 |

## $\mathrm{H}_{0}$ : No association between HRT

 and hip fracture
## Conclusion

- Reject null hypothesis
- There was association between HRT and hip fracture
. mcc case control


Note: if number of discordant pairs is less than 20, the Exact McNemar's test is more appropriate
Wiadarn of the Land

## Hypothesis testing for categorical data



II. Hypothesis testing

- Categorical outcome
- Continuous outcome


## Hypothesis testing for continuous data



Single group
Two groups

- Independent sample
- Paired sample

Three groups or more

## Hypothesis testing for continuous data



## Single group

Two groups

- Independent sample
- Paired sample


## Three groups or more

## Independent sample

- Comparison of systolic blood pressure between men and women.
© Comparison of cholesterol level between patients with and without chronic kidney disease.


## Statistical test for two independent groups

| Distribution | Parameter | Statistical test |
| :--- | :---: | :---: |
| Normal | Mean | - Student t-test with equal variance |
|  |  | - Student t-test with unequal variance |
| Non-normal | Median | - Mann-Whitney test, |
|  |  | - Quantile regression |

## Example I:

D Researchers wanted to test if means/median of weights of HIV patients who received NVP, and HIV patients who received EFV, are different.

## Variance ratio test



## Conclusion

V Variances between two groups are not different.

## Wiadom of the Land

## Student t-test with equal variance



Conclusion
© Mean weights between two groups are not different.

## Example II:

- Researchers wanted to test if CD4 count of HIV patients who received NVP, and HIV patients who received EFV, are different.

Faculty of Medicine Ramathibodi Hospital Department of Clinical Epidemiology and Biostatistics

## Ouantile regression



## Dummy table for two groups comparison

| Characteristics | NVP | EFV | P value |
| :--- | :---: | :---: | :---: |
|  | Mean (SD) | Mean (SD) |  |

Age (year)


## Weight (kg)

Height (cm)
BMI (kg/m $\left.{ }^{3}\right)$
CD4 count; median (range)

## Paired sample

- Comparison of systolic blood pressure before and after used of OC in pre-menopausal women.

○ In matched case-control study, matched by age and sex, which aim to compare oral hygiene index between periodontitis and non-periodontitis patients.

## Statistical test for paired sample

| Distribution | Parameter | Statistical test |
| :--- | :---: | :---: |
| Normal | Mean | Paired t-test |
| Non-normal | Median | Wilcoxon matched signed-rank test |

## Example III:

- Researchers wanted to test if mean weights of HIV patients before and after receiving an antiretroviral therapy regimen are different.


## Paired t-test



## Example IV:

- Researchers wanted to test if median of CD4 count of HIV patients before and after receiving an antiretroviral therapy regimen are different.


## Wilcoxon matched signed-rank test

## Conclusion <br> © Reject null hypothesis <br> - Median CD4 count before and after receiving regimen are different

```
. signrank cd4c0= cd4c12
```

    Wilcoxon signed-rank test
        sign | obs sum ranks expected
    


> Wiadarn of the Land


